T-VEC in Melanoma
Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.
Watch
Cyclin-Dependent Kinases and the Treatment of Cancer
Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.
Using the Immune System to Fight Cancer
Andre Goy, MD, from John Theurer Cancer Center, discusses recent research into fighting cancer with the immune system.
Hsp90 Inhibition With Ganetespib as a Lung Cancer Treatment
Suresh S. Ramalingam, MD, from the Winship Cancer Institute, discusses the investigation of the heat shock protein 90 inhibitor ganetespib as a treatment for patients with advanced lung cancer.
Repurposing Drugs to Treat Thyroid Cancer
Marcia Brose, MD, PhD, from the University of Pennsylvania, on repurposing drugs to treat thyroid cancer.
The Next Steps for Bevacizumab in Recurrent Cervical Cancer
Krishnansu S. Tewari, MD, from the University of California, Irvine, comments on the next steps for bevacizumab for recurrent cervical cancer.
ASCO's CancerLinQ Program
Clifford A. Hudis, MD, describes ASCO's CancerLinQ program, which is a direct response to the Insitute of Medicine's call for rapid learning systems.
The Design of a Trial Analyzing Selumetinib in Advanced Uveal Melanoma
Richard D. Carvajal, MD, describes the design of a phase II study of selumetinib versus temozolomide in gnaq/Gna11 mutant uveal melanoma.
Personalizing Treatment of Early-Stage Breast Cancer
Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.
Using the BROCA Genetic Assay to Treat Breast Cancer
Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.
The Changing Outlook for Immunotherapies in Cancer Treatment
Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.
Ellen Matloff Discusses Genetic Testing and Counseling in Cancer Care
Ellen T. Matloff, MS, CGC, discusses genetic testing, counseling, and the implications of the US Supreme Court decision to ban the patenting of genes.
Richard Gray on the Safety and Efficacy of 10 Years of Adjuvant Tamoxifen
Richard G. Gray, MA, MSc, discusses results from the randomized, phase III aTTom study that examined 10 years of tamoxifen versus the more standard 5 years.
Low Testosterone in Patients With ALK-Positive Lung Cancer
D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, comments on ALK-positive lung cancer patients with low testosterone.
The Efficacy of Nivolumab in Advanced Melanoma
Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from a phase I trial investigating the anti-PD-1 monoclonal antibody nivolumab.
Treatment With Radium-223 and Chemotherapy for Prostate Cancer
Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Maintenance Pazopanib in Ovarian Cancer
Andreas du Bois, MD, discusses the background, rationale, and results for the exploration of maintenance pazopanib as a treatment for patients with advanced ovarian cancer.
Recent Progress on the Molecular Front for the Treatment of Prostate Cancer
A. Oliver Sartor, MD, Director of the Tulane Cancer Center, discusses the recent progress for the treatment of prostate cancer.
Crizotinib Versus Chemotherapy in ALK-Positive NSCLC
Alice T. Shaw, MD, PhD, describes a trial comparing crizotinib and chemotherapy in patients with advanced ALK-positive non-small cell lung cancer.
Frontline Bevacizumab in Glioblastoma
Mark R. Gilbert, MD, reviews the trial design and findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.
The Mechanism of Action and Development of Moxetumomab Pasudotox
Edward Bradley, MD, gives an overview of the mechanism of action and development of moxetumomab pasudotox, a monoclonal antibody directed at CD22.
The Phase I Trial of IPI-145 in Hematologic Malignancies
Julian Adams, PhD, President, Research and Development, Infinity Pharmaceuticals, describes a phase I trial of IPI-145, a potent inhibitor of PI3KEδ and PI3K-γ.
The Benefit of Generic Drug User Fees
Richard L. Schilsky, MD, from University of Chicago Comprehensive Cancer Center, explains the benefit to generic drug user fees.
The Future of Palbociclib for the Treatment of Breast Cancer
Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.
An Overview of the Practice-Changing Information From the 2013 ASCO Meeting
Sandra Swain, MD, from the Washington Cancer Institute at MedStar Washington Hospital Center, on the practice-changing information from the 2013 ASCO Meeting.
The Efficacy of Lambrolizumab in Advanced Melanoma
Antoni Ribas, MD, PhD, comments on the efficacy of lambrolizumab, an anti-PD-1 antibody, in patients with advanced melanoma.
The Development of Prophage G-200 Vaccine for Recurrent Glioblastoma Multiforme
Andrew T. Parsa MD, PhD, describes the development and trial involving prophage G-200, a vaccine for recurrent glioblastoma multiforme.
Sorafenib in RAI-Resistant Differentiated Thyroid Cancer
Marcia Brose, MD, PhD, discusses the rationale, background, and results from the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.
The Benefits of a Breakthrough Therapy Designation
Richard Pazdur, MD, from the FDA’s Center for Drug Evaluation and Research, describes the benefits of a Breakthrough Therapy Designation.
MPDL3280A for Non-Small Cell Lung Cancer
Roy S. Herbst, MD, PhD, comments on the emergence of immunotherapies for multiple types of cancer including MPDL3280A for non-small cell lung cancer.